Ten patients with atherosclerotic stenosis or occlusion of the iliac artery were treated with Gianturco expandable metallic stents. In the five cases of stenosis, only balloon dilation was performed prior to placement of stents. The five patients with occluded arteries were given intraarterial infusions of urokinase before balloon dilation and stent placement. Clinical symptoms improved in all patients, and no technical failures or complications occurred. Doppler ankle-brachial index studies were performed in nine cases, and in all nine cases the indexes improved after stent placement. During follow-up of 2-18 months (mean, 10.3 months), all arteries remained patent. Follow-up angiograms showed slight intimal thickening and no restenosis. Long-term follow-up and more clinical experience will be necessary to evaluate the efficacy of this stent. However, preliminary results suggest that the Gianturco expandable metallic stent is of value in the treatment of arterial occlusive disease.
multticenter post-market registry of the ultra-low profile (14 F) Ovation Prime stent graft when used in the treatment of patients with AAA using a fast-track protocol, consisting of appropriate patient selection, bilateral percutaneous access, avoidance of general anesthesia and intensive care unit admission, and next-day discharge. A total of 250 subjects will be enrolled at up to 40 sites in the United States. The first subject in this study was enrolled in October 2014 and enrollment is anticipated to continue through mid-2016. Results: The primary endpoint of the LIFE registry is the incidence of major adverse events (MAE) through 30 days' follow-up. All adverse events are adjudicated by a Clinical Events Committee. Secondary endpoints of the LIFE registry include operative details, technical success, procedure-and device-related complications, patient convalescence, and ability to successfully complete all components of the fast-track protocol. Patients will be followed in the LIFE registry for 30 days posttreatment. Conclusions: The recent development of ultra low-profile stent grafts enables EVAR using least invasive methods. A structured fast-track EVAR protocol may yield clinical and cost benefits versus standard EVAR.
po0.001). In the TIPS for variceal bleeding subset, variceal occlusion significantly decreased recurrent variceal hemorrhage rates (bTIPS 25.9%, bEMB 7.7%, bSEM 9.5%, p ¼ 0.04; bEMB vs bTIPS: OR 0.24, p ¼ 0.07; bSEM vs bTIPS: OR 0.30, p ¼ 0.02). bEMB and bSEM did not differ in rebleeding rates (OR 1.26, p ¼ 0.78). Rates of reintervention for bleeding did not significantly differ (bTIPS 5.5%, bEMB 0.0%, bSEM 4.8%, p ¼ 0.74). Conclusions: Variceal occlusion after TIPS placement reduces rebleeding risk in patients undergoing TIPS for variceal bleeding. Sclerosis may not provide additive benefit over embolization. Analysis is limited by low adverse event rate.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.